Commentary: Tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - Authors' reply

摘要

We agree with Bradshaw and Danta that the findings of this study should be confirmed in a prospective study with longer follow-up times and a greater number of patients, particularly for tenofovir. As the study focuses on a real-life setting, our data may indeed reflect differences specific to the study population.